EMD

0.00%

5.1¢

EMYRIA LIMITED

Market Cap $18.69M Add to my watchlist

Healthcare

Emyria Limited is an Australia-based clinical services and drug development company. The... Emyria Limited is an Australia-based clinical services and drug development company. The Company is focused on developing patient outcomes in neuroscience and mental health through its clinical service delivery, proprietary real-world data (RWD), and drug discovery & development. It delivers evidence-based and emerging therapies for mental health and other unmet needs through its Emerald Clinics and the Pax Centre. Emerald Clinics specializes in providing treatments for patients with complex and chronic conditions. The Pax Centre specializes in treating individuals grappling with the psychological impacts of traumatic experiences. Through its advanced data platform operated by Palantir, the Company collects robust and ethically sourced real-world data to improve its care models and support its distinct therapy and drug development initiatives. The Company is also developing several proprietary ultra-pure cannabinoid dose forms and advancing them towards registration, such as EMD-RX5.More

NATURAL MEDICINE LEADERS

ASX-listed wellness consumer discretionary player Calmer Co (ASX:CCO) has revealed its e-commerce sales hit more than $10K per day in March.

Latest Threads

Tag

Subject

EMD

Ann: March 2024 Quarterly Activities Report and Appendix 4C

03/05/24

4.0K

03/05/24

Last post rasberry

4.0K

EMD

CEO Podcast

23/04/24

409

23/04/24

Last post gavint66

409

EMD

News: EMD Emyria Receives Bids Of A$2.3M To Expand Clinical Services

23/04/24

120

23/04/24

Last post

Hot News

120

EMD

Ann: Proposed issue of securities - EMD

23/04/24

166

23/04/24

Last post

ASX News

166

EMD

Ann: Emyria Receives Bids of $2.3M to Expand Clinical Services

23/04/24

245

23/04/24

Last post

ASX News

245

EMD

Ann: Trading Halt

22/04/24

3.9K

22/04/24

Last post FiSaver

3.9K

EMD

News: EMD Emyria Seeks Trading Halt

19/04/24

129

19/04/24

Last post

Hot News

129

EMD

Ann: Emyria Opens Empax Centre to Advance Mental Health Care

10/04/24

1.3K

10/04/24

Last post mc3456

1.3K

See All Discussions

Timeline

March 2024 Quarterly Activities Report and Appendix 4C
26 Apr 08:40	Share

Proposed issue of securities - EMD
23 Apr 09:54	Share

Emyria Receives Bids of $2.3M to Expand Clinical Services
23 Apr 09:53	Share

Trading Halt
19 Apr 09:14	Share

Emyria Opens Empax Centre to Advance Mental Health Care
10 Apr 08:23	Share

Emyria Expands Specialist AP Team - First Female for MDMA-AT
05 Apr 08:25	Share

Emyria, Reach Wellness Enter MDMA-AT Research Agreement
03 Apr 08:25	Share

Notification of cessation of securities - EMD
19 Mar 18:19	Share

Response to ASX Aware Query
12 Mar 17:58	Share

Response to ASX Price Query
08 Mar 09:56	Share

Emyria Half Year Results FY2024
29 Feb 09:25	Share

Appendix 4D and Half Year End Financial Report
28 Feb 17:28	Share

Notification of cessation of securities - EMD
23 Feb 19:47	Share

Webinar Presentation
02 Feb 08:23	Share

December 2023 Quarterly Activities Report and Appendix 4C
31 Jan 09:32	Share

Notification of cessation of securities - EMD
30 Jan 11:11	Share

Emyria Receives $2.5M R&D Tax Incentive Refund
15 Jan 09:29	Share

Company Overview and Strategic Update
10 Jan 09:31	Share

Emyria Specialist Granted Authorised Prescriber Status
10 Jan 09:28	Share

Change of Director's Interest Notice - M. Winlo
02 Jan 19:43	Share

Change in Substantial Holding
27 Nov 08:21	Share

Notification of cessation of securities - EMD
27 Nov 08:19	Share

Initial Director's Interest Notice - G. Hutchinson
22 Nov 08:59	Share

Final Director's Interest Notice - S. Washer
22 Nov 08:58	Share

Eminent Healthcare Leader New Independent Non-Exec Chair
21 Nov 09:45	Share

Application for quotation of securities - EMD
21 Nov 09:42	Share

Results of Annual General Meeting
16 Nov 12:28	Share

Final Director's Interest Notice - A. Vickery
13 Nov 18:47	Share

Board Changes and Executive Restructuring
13 Nov 08:23	Share

Section 708A(5)(e) Notice
10 Nov 17:50	Share

View More

(20min delay)
Last 5.1¢		Change 0.000(0.00%)		Mkt cap ! $18.69M

Open	High	Low	Value	Volume
5.0¢	5.1¢	4.9¢	$5.163K	105K

Buyers (Bids)

No.	Vol.	Price($)
1	25000	5.0¢

Sellers (Offers)

Price($)	Vol.	No.
5.1¢	38827	1

View Market Depth

No.	Vol.	Price($)
1	25000	0.050
3	215869	0.049
1	25006	0.048
1	11000	0.047
1	200000	0.046

Price($)	Vol.	No.
0.051	38827	1
0.052	65193	1
0.053	10000	1
0.062	51000	1
0.064	125693	2

Last trade - 15.00pm 03/05/2024 (20 minute delay)

EMD (ASX) Chart

EMYRIA LIMITED

Latest Threads

8th Regional Uranium Anomaly Confirmed at Saraya Project - Potential for new discoveries still exists!

Timeline

Featured News

Latest Videos

Emyria (ASX:EMD) recruits first patient in MDMA-assisted therapy trial for PTSD

10 Jul 2023 12:47 (AEST)

Emyria (ASX:EMD) pockets more than $2m R&D tax refund

12 Jan 2023 10:34 (AEDT)

Latest Articles

Emyria locks in $2.3M to progress MDMA research – with Chair adding $0.3M

WA-based and ASX-listed Emyria is seeking to further research using MDMA to treat PTSD. The chair has funded the company $0.3M on Tuesday.

Emyria launches Empax Centre - pioneering innovation in mental health treatment

Emyria Limited has opened the Empax Centre, a cutting-edge facility designed to advance innovative mental health treatments, including psychedelic-assisted therapies.

Emyria hits milestone in PTSD treatment with first female specialist for MDMA therapy

Emyria has nominated its first female psychiatrist to treat post-traumatic stress disorder using the drug ecstasy.

Buyers (Bids)

Sellers (Offers)

Top Stories

Featured News